Your Article Summary
See Latest ArticlesEtanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis
International Journal of Dermatology, 01/22/08
Yamauchi P et al. - Methotrexate, the most common systemic small molecule used in the treatment of moderate to severe psoriasis, is associated with significant toxicities and adverse events. Long-term continuous usage is not recommended due to potential liver toxicity, myelosuppression, and other side effects. Abrupt cessation of methotrexate without tapering can lead to flare-up and rebound of psoriasis. Here we describe sustained clinical responses in 6 patients with psoriasis following gradual cessation of methotrexate through the addition of etanercept therapy
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases
Current Medical Research and Opinion, 12/18/09
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
Clinical Interventions in Aging, 12/18/09
Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome
European Journal of Pain, 12/18/09